Acurx Pharma Q3 net loss $4.6M; Phase 2b enrollment underway

Acurx Pharmaceuticals, Inc.

2021-Q3 EPS reported -$1.27

Net loss of $4.6M ($0.46/diluted share) for Q3 2021 vs. $1.3M ($0.21) in Q3 2020.
Cash balance $14.5M as of Sep 30, 2021; R&D spend $1.1M (up from $0.7M) on Phase 2b costs.
Phase 2b trial for C. difficile infection (ibezapolstat) enrollment started; completion expected Q3 2022.
Phase 2a data showed 100% clinical cure, 100% sustained cure, beneficial microbiome changes.
New collaboration with Leiden University to study DNA pol IIIC enzyme mechanism of action.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.